PRO Share Price Performance
د.م1,339.00
219.00 (19.55%)
46.5% overvalued intrinsic discount
د.م914.16
Fair Value
Price د.م1,339.00
Abdouahed د.م914.16
Fair Valueد.م914.16
Share Pricen/a
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
PRO Community Narratives
AB
Fair Value
·Fair Value د.م914.16 46.5% overvalued intrinsic discount
Promopharm S.A. has shown resilience in the Moroccan pharmaceutical market.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Promopharm S.A. has shown resilience in the Moroccan pharmaceutical market.
Considerations for the Next Five Years: Product Innovation: The company's recent revenue growth is partly attributed to the success of newly launched products. Continuous innovation and development of new pharmaceuticals will be crucial for sustaining growth. Market Dynamics: The pharmaceutical industry is subject to regulatory changes, competitive pressures, and evolving healthcare needs.Read more
AB
د.م914.16
46.5% overvalued intrinsic discount
Fair Value
Revenue
18.84% p.a.
Profit Margin
7.06%
Future PE
17.58x
Price in 2030
د.م2.37k
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AB
Promopharm S.A. has shown resilience in the Moroccan pharmaceutical market.
Fair Value: د.م914.16 46.5% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Societe de Promotion Pharmaceutique du Maghreb S.A. Key Details
About PRO
- Founded
- 1947
- Employees
- n/a
- CEO
- WebsiteView website
Societe de Promotion Pharmaceutique du Maghreb S.A. manufactures and markets pharmaceutical and dermo-cosmetic products in the United States, Canada, and internationally. It provides its products for therapeutic areas, including respiratory, oncology, and pain management. It also offers injectable, and oral and respiratory manufacturing capabilities. The company was founded in 1947 and is based in Casablanca, Morocco. Societe de Promotion Pharmaceutique du Maghreb S.A. is a subsidiary of Hikma Pharmaceuticals PLC.
